Clinical Trial Update: Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007) [Phase 2]

View source ↗

Summary

Phase 2 trial REGEN-007 evaluating Renal Autologous Cell Therapy (REACT) in adults with type 1 or type 2 diabetes and chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• REACT Renal Autologous Cell Therapy

Snippet

Sponsor: Prokidney | Conditions: Chronic Kidney Diseases, Type 1 Diabetes Mellitus | Phase 2 | Status: COMPLETED